Related Experiment Videos
[Neuroblastoma: diagnosis and therapy]
U Wargalla-Plate1, B Hero, F Berthold
1Klinik für Kinderheilkunde, Universität zu Köln.
Praxis
|October 10, 1995
Summary
Neuroblastoma prognosis heavily relies on disease stage, with stage 4 having a poor survival rate. Comprehensive assessment of factors like age and tumor extent is crucial for tailored neuroblastoma treatment.
Area of Science:
- Pediatric Oncology
- Cancer Genomics
- Tumor Biology
Context:
- Neuroblastoma is a significant pediatric cancer.
- Prognosis varies widely based on disease characteristics.
- Current treatment strategies require precise prognostic evaluation.
Purpose:
- To elucidate the key prognostic factors in neuroblastoma.
- To emphasize the importance of disease extent in determining patient outcomes.
- To highlight the need for a stage- and risk-adapted therapeutic approach.
Summary:
- Neuroblastoma prognosis is predominantly determined by the stage of the disease.
- Survival rates significantly decrease from stages 1-3 (94-66%) to stage 4 (<20%).
- Extent of disease is the primary prognostic indicator, supplemented by age, lactate dehydrogenase (LDH) levels, tumor resectability, and molecular/cytologic parameters.
Impact:
- Informs clinical decision-making for neuroblastoma patients.
- Facilitates the development of personalized treatment protocols.
- Aids in stratifying patients for risk-adapted therapies, improving survival outcomes.